SOURCE: Aldagen, Inc.

May 04, 2007 11:51 ET

Aldagen Announces Participation in Breakout Session and Business Forum at 2007 BIO International Convention

DURHAM, NC -- (MARKET WIRE) -- May 4, 2007 --Aldagen, Inc., a biotechnology company advancing a pipeline of clinical-stage regenerative therapies, today announced that it will be participating in a Breakout Session entitled "Adult Stem Cells: Current Medical and Business Challenges and Opportunities" at the 2007 BIO International Convention. In addition, the company will be presenting at the BIO Business Forum during the conference. The conference is taking place at the Boston Convention & Exhibition Center.

On Tuesday, May 8 at 11:30 a.m., Ed Field, President and COO of Aldagen, will give a corporate presentation at the 2007 BIO Business Forum in Room A. During the presentation, Mr. Field will provide an overview of the company including recent clinical and strategic developments.

On Wednesday, May 9 at 2:00 p.m., W. Thomas Amick, Chairman and CEO of Aldagen, will be participating in a Breakout Session entitled "Adult Stem Cells: Current Medical and Business Challenges and Opportunities" in Room 252 AB. The session will focus on the clinical and business opportunities and challenges with using adult stem cells to treat a variety of diseases.

About Aldagen, Inc.

ALDAGEN is a biotechnology company advancing a pipeline of clinical-stage regenerative therapies. The Company has three product candidates in clinical development for chronic heart failure, critical limb ischemia and pediatric metabolic disorders and malignancies. ALDAGEN's therapeutics are produced by a proprietary technology platform that selects and delivers potent, adult stem and progenitor cells for therapeutic use. The platform yields a broad range of therapeutic cells that can be used rapidly, without culture or expansion. To learn more about ALDAGEN, please visit www.aldagen.com.

Contact Information